home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Karuna Therapeutics Shares Are Trading Sharply Lower ↗

December 06, 2022

Karuna Therapeutics Inc (NASDAQ: KRTX) shares are trading lower by 11.63% to $200.56 going into the close of Tuesday's session after the company announced a CEO transition. What Happened?

Via Benzinga

Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer

December 06, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

Looking Into Karuna Therapeutics's Return On Capital Employed ↗

November 23, 2022

Via Benzinga

My 3 Top Biotech Stock Picks for 2023 ↗

November 22, 2022

Biotech stocks are set to shine in 2023.

Via The Motley Fool

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Karuna Therapeutics: Q3 Earnings Insights ↗

November 03, 2022

Karuna Therapeutics (NASDAQ:KRTX) reported its Q3 earnings results on Thursday, November 3, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

12 Analysts Have This to Say About Karuna Therapeutics ↗

November 01, 2022

Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for Karuna Therapeutics ↗

September 13, 2022

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter:

Via Benzinga

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates

November 03, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

What 12 Analyst Ratings Have To Say About Karuna Therapeutics ↗

November 01, 2022

Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Mizuho Is Bullish On This Schizophrenia-Focused Stock, Read Why ↗

August 23, 2022

Via Benzinga

Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference

November 01, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

2 On-Fire Biotech Stocks That Are Crushing the Bear Market ↗

October 31, 2022

The biotech sector is down this year, but these two biopharmaceutical stocks have delivered strong returns.

Via The Motley Fool

Opportunities In Large Cap Growth And Small Cap ↗

October 20, 2022

The third quarter was true

Via Talk Markets

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

October 11, 2022

From PsychoGenics Inc.

Via Business Wire

Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress

October 06, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

Where Karuna Therapeutics Stands With Analysts ↗

September 29, 2022

Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

7 Momentum Stocks to Buy Now for Extraordinary Gains ↗

September 26, 2022

Momentum stocks aren't as risky as some say, and these winning stocks are strong examples for investors to consider.

Via InvestorPlace

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗

September 20, 2022

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

Via Talk Markets

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Where Karuna Therapeutics Stands With Analysts ↗

September 13, 2022

Over the past 3 months, 12 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

What 12 Analyst Ratings Have To Say About Karuna Therapeutics ↗

September 13, 2022

Within the last quarter, Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings:

Via Benzinga

Karuna Therapeutics to Present at Upcoming Investor Conferences

September 01, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

This Analyst Raises PT On Karuna Therapeutics By 100%; Wells Fargo Predicts $2,300 For This Stock ↗

August 15, 2022

Piper Sandler boosted the price target on First Solar, Inc. (NASDAQ: FSLR) from $120 to $165. Piper Sandler analyst Kashy Harrison maintained an Overweight rating on the stock. First Solar shares rose...

Via Benzinga

Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

August 12, 2022

From Karuna Therapeutics, Inc.

Via Business Wire

Coinbase, Trade Desk, H&R Block And Some Other Big Gainers From Wednesday ↗

August 11, 2022

U.S. stocks closed higher on Wednesday following the release of inflation data. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com